ADRC Composition for Liver Fibrosis via Intra-arterial Injection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic liver diseases such as liver fibrosis and cirrhosis are inadequate, with existing therapies failing to effectively prevent progression to terminal conditions, and there is a lack of effective methods for improving hepatic reserve in liver cancer patients, leading to invasive and costly liver transplantation and poor prognosis.
Innovation Solution
A pharmaceutical composition containing adipose-derived regenerative cells (ADRCs), including adipose-derived stem cells, endothelial cells, and other cell types, is administered to improve and maintain hepatic functions, specifically formulated to be administered via intra-arterial or intraportal injection to target the liver, promoting angiogenesis and anti-fibrosis to treat liver fibrosis and cirrhosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If liver transplantation is performed to treat terminal liver disease, then patient survival is improved, but medical costs increase drastically and donor shortage remains
Solution Approach 1:
The patent uses adipose-derived regenerative cells as a less expensive alternative to liver transplantation. These cells can be harvested from the patient's own adipose tissue, expanded in culture, and administered to treat liver fibrosis and cirrhosis, providing a cost-effective therapy that avoids the need for expensive transplanted organs while still improving patient outcomes
Solution Approach 2:
The patent employs autologous adipose-derived regenerative cells, meaning the patient's own cells are harvested from their adipose tissue and used to treat their liver disease. This self-service approach eliminates the need for donor organs and reduces immunosuppression requirements, thereby reducing medical costs while maintaining treatment effectiveness
2Reliability
If liver transplantation is performed, then patient survival is improved, but the procedure becomes highly invasive
Solution Approach 1:
The patent extracts regenerative cells from adipose tissue through minimally invasive liposuction procedures, rather than performing major surgical transplantation. The cells are then administered to the patient to treat liver disease, replacing the need for invasive liver transplantation while achieving similar therapeutic goals
Solution Approach 2:
The patent uses adipose-derived regenerative cells as an intermediary substance that mediates the treatment of liver disease. Instead of directly transplanting liver tissue or organs, these regenerative cells act as intermediaries that promote liver regeneration and functional improvement through a less invasive route
3Adaptability or versatility
If hepatic reserve is not improved in liver cancer patients, then radical treatment options are limited, but without improvement surgical resection and radiofrequency ablation cannot be performed
Solution Approach 1:
The patent administers adipose-derived regenerative cells to preliminarily improve hepatic reserve and liver function before cancer patients undergo radical treatments such as surgical resection or radiofrequency ablation. This preliminary enhancement of liver function enables patients to tolerate and benefit from these aggressive treatments that would otherwise be contraindicated due to poor hepatic reserve
Data Source
AI summary
There is a pharmaceutical composition having adipose-derived regenerative cells (ADRCs) for use in prevention or treatment of liver fibrosis or liver cirrhosis. The composition is effective in maintaining and improving hepatic function and preventing and treating liver fibrosis or liver cirrhosis.